Bullish
Verastem (Nasdaq: VSTM) reports RAMP 205 pancreatic data and starts KRAS G12D trial
Verastem Oncology has announced encouraging early results from its RAMP 205 trial for first-line metastatic pancreatic cancer, showing an 86% six-mont...